Magle Chemoswed Holding AB (publ) (STO:MAGLE)

Market Cap	241.60M -65.1%
Revenue (ttm)	300.49M +43.6%
Net Income	-26.60M
EPS	-1.32
Shares Out	20.65M
PE Ratio	n/a
Forward PE	14.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,720
Average Volume	5,197
Open	11.50
Previous Close	11.40
Day's Range	11.40 - 12.00
52-Week Range	10.50 - 35.20
Beta	0.12
RSI	29.69
Earnings Date	Feb 27, 2026

About STO:MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 144
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2024, STO:MAGLE's revenue was 240.57 million, an increase of 40.27% compared to the previous year's 171.50 million. Earnings were 11.94 million, a decrease of -1.91%.